All In MedTech

Device Trial Radar · NCT04900623

Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study

Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

145

Planned (sponsor's estimate)

Start

Jul 2, 2021

Primary completion

Jun 1, 2030

Study completion Jun 1, 2032

Sponsor

Lead sponsor
Jonathan Schoenfeld, MD, MPHAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Naveris
First posted
May 25, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research is being conducted to understand if treatment can be tailored for participants with HPV-related oropharynx cancers using both clinical features (stage of the tumor, smoking status) combined with an investigational HPV blood test. The names of the test and treatments involved in this study are: * NavDx® HPV ctDNA testing (HPV blood test) * Radiation therapy * Chemotherapy: Cisplatin, or Carboplatin and Paclitaxel (not all participants receive any or all of these agents)

Conditions

  • HPV-Associated Oropharyngeal Squamous Cell Carcinoma
  • HPV Positive Oropharyngeal Squamous Cell Carcinoma
  • HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage
  • HPV-Related Squamous Cell Carcinoma
  • Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage
  • HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic Stage

Interventions

  • NavDx HPV ctDNA TestingDevice

    Blood will be collected and shared with an outside lab for analysis. This test will be done at Week 4 and at End of Treatment. This test will be done at at End of Treatment and in follow-up at 3, 6, 9, and 12 months after completing the study treatment. In years 2 and 3 after treatment, the test will be collected every 6 months or twice a year. The specimens will be identifiable. The specimens will be banked for future use.

  • RadiotherapyRadiation

    Radiation Therapy (administered daily, Monday-Friday). Higher risk participants will receive standard radiation dose for up to 7-8 weeks. Lower risk participants will receive a lower dose and treatment will only last 5-6 weeks.

  • Chemotherapy drugDrug

    Chemotherapy and radiation therapy are both considered standard treatments * Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses. * Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival 2 YearsTime frame: 2 Years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.